Physician profile

Daniel C Desimone

Internal Medicine · Crestwood, IL

NPI 1447246822

$1,053.56

in general payments reported to CMS, 2019-2025

21 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $138.10 2019-2021
Astrazeneca Pharmaceuticals LP $106.16 2020-2022
Lilly USA, LLC $104.64 2021-2022
Amarin Pharma, INC. $76.83 2020-2022
Abbvie INC. $76.27 2021-2022
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $69.48 2020-2022
Janssen Pharmaceuticals, INC $67.62 2020
Pfizer INC. $65.80 2021-2022
Novartis Pharmaceuticals Corporation $55.05 2022
Eisai INC. $37.88 2020
Sanofi-Aventis U.S. LLC $37.18 2019-2021
Bayer Healthcare Pharmaceuticals INC. $31.89 2021
Biohaven Pharmaceutical Holding Company LTD. $30.47 2022
Glaxosmithkline, LLC. $30.37 2022
Medtronic, INC. $20.08 2021
Show all 21 companies
CompanyGeneral paymentsYearsTop products
Boehringer Ingelheim Pharmaceuticals, INC. $19.17 2022
E.R. Squibb & Sons, L.L.C. $18.86 2021
Amgen INC. $18.75 2022
Vivus LLC $18.50 2020
Allergan, INC. $16.51 2020
Abbott Laboratories $13.95 2021

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Daniel C Desimone

$1,053.56

in general payments reported 2019-2025

Years
2019-2022
Top company
Novo Nordisk INC

https://glasscript.com/doctor/717728/daniel-c-desimone

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.